Society categorizes patients based on risk associated with delaying services.
While breast imaging services have largely been discouraged during the COVID-19 pandemic, postponing these scans isn’t the best options for every patient. For women with breast cancer, waiting for imaging could put them at greater risk.
To help providers determine which patients – and which particular situations – are most appropriate for imaging during the outbreak, the American Society of Breast Surgeons published recommendations for when services should, and should not, be completed.
“These recommendations should be taken in the context of each institution’s resources and prevalence of the COVID-19 pandemic in their region,” the American Society of Breast Surgeons (ASBS) wrote. “The COVID-19 pandemic may vary in severity over time, and these recommendations are subject to change with changing COVID-19 pandemic severity.”
ASBS leaders placed patients into three categories:
According to the published guidance, there are no circumstances in which patients would fall under Priority A for breast imaging. However, situations do exist for Priority B and Priority C services, they said.
Specifically, the Priority B category includes diagnostic imaging for breast symptoms or a BI-RADS 4-5 screening mammogram, as well as biopsies for abnormal mammograms or breast symptoms. Given the recommendation against any new screening mammograms until the pandemic subsides, it is likely these services would have been previously scheduled.
For Priority C, all services can be deferred for a later date. Routine screening mammograms can be deferred for up to 12 months in the general population without a likely impact on overall survival, and patients with previous abnormal screenings can wait for six months before pursuing imaging again. In addition, all screenings with other modalities, including MRI and breast ultrasound, should also be postponed.
As with all non-emergent services during this time, radiologists and other providers should couple their best judgment with recommended guidelines to ensure they’re providing the safest care possible, according to a team led by Emilia Diego, M.D., director of the Pre-Menopausal Breast Cancer Program at the University of Pittsburg Medical Center.
“Although medical centers must continue to offer care that cannot be postponed for months for some non-COVID-19 related conditions, such as cancer, the benefits of this care should be balanced against the risk of COVID-19 exposure for patients and staff during this pandemic,” Diego wrote in an editorial published in the European Journal of Breast Health. “For each breast cancer patient, the risk/benefit ratio should be considered.”
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.